Search our Database of Scientific Publications and Authors

I’m looking for a

    3553 results match your criteria Oral Malignant Melanoma

    1 OF 72

    Therapeutic Anticoagulation in Patients with Primary Brain Tumors or Secondary Brain Metastasis.
    Oncologist 2017 Nov 20. Epub 2017 Nov 20.
    Memorial Sloan Kettering Cancer Center, New York City, New York, USA.
    Patients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. Read More

    Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.
    Oncotarget 2017 Oct 12;8(49):85516-85525. Epub 2017 Aug 12.
    AntiCancer, Inc., San Diego, CA, USA.
    An excessive requirement for methionine termed methionine dependence, appears to be a general metabolic defect in cancer. We have previously shown that cancer-cell growth can be selectively arrested by methionine deprivation such as with recombinant methioninase (rMETase). The present study used a previously-established patient-derived orthotopic xenograft (PDOX) nude mouse model of BRAF V600E-mutant melanoma to determine the efficacy of rMETase in combination with a first-line melanoma drug, temozolomide (TEM). Read More

    P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice.
    Pharmacol Res 2017 Nov 14. Epub 2017 Nov 14.
    The Netherlands Cancer Institute, Division of Pharmacology, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address:
    Encorafenib (LGX818) is a promising BRAF(V600E) inhibitor that has efficacy against metastatic melanoma. To better understand its pharmacokinetics, we studied its interactions with the multidrug efflux transporters ABCB1 and ABCG2 and the multidrug metabolizing enzyme CYP3A. In polarized MDCK-II cells, encorafenib was efficiently transported by canine and human ABCB1 and ABCG2 and by mouse Abcg2. Read More

    Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases.
    J Cancer 2017 17;8(18):3828-3837. Epub 2017 Oct 17.
    Department of Oral and Maxillofacial-Head and Neck Oncology, Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, 200011, China.
    Background: To investigate the relationship between clinical and histopathological characteristics and overall survival of patients with oral mucosal melanoma (OMM) without distal metastasis in order to provide predictive prognostic information of OMM. Methods: Ki67 expression was assessed by immunohistochemistry in 123 patients with OMM without distant metastases. The associations between Ki67 expression and clinical features and overall survival (OS) of patients were statistically analyzed. Read More

    Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial.
    Eur J Cancer 2017 Nov 14;87:147-163. Epub 2017 Nov 14.
    Gustave Roussy, Department of Medical Oncology, Villejuif, France.
    Purpose: Papillary renal-cell carcinoma type 1 (PRCC1) is associated with MET gene alterations. Our phase II trial prospectively assessed the efficacy and safety of crizotinib in patients with advanced/metastatic PRCC1 with or without MET mutations (MET+ and MET-).

    Experimental Design: Eligible patients with reference pathology-confirmed PRCC1 received 250 mg oral crizotinib twice daily. Read More

    The clinical significance of c-Kit mutations in metastatic oral mucosal melanoma in China.
    Oncotarget 2017 Oct 31;8(47):82661-82673. Epub 2017 Jul 31.
    Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200011, China.
    c-Kit mutations are frequently detected in mucosal melanomas, but their clinical significance in metastatic oral mucosal melanomas (OMM) remains unclear. The main purpose of this study was to investigate the clinical and pathological features of metastatic OMMs with c-Kit mutations and the efficiency of the tyrosine kinase inhibitor imatinib in treating metastatic OMMs. We found thatresidual primary lesion and neck lymph nodes could act as independent prognostic factors in metastatic OMM patients. Read More

    Lipocalin-type prostaglandin D synthase-derived PGD2 attenuates malignant properties of endothelial cells in tumor.
    J Pathol 2017 Nov 10. Epub 2017 Nov 10.
    Department of Animal Radiology, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Tokyo, Japan.
    Endothelial cells (ECs) are a key component of the tumor microenvironment. They have abnormal characteristics compared to the ECs in normal tissues. Here, we found a marked increase in lipocalin-type prostaglandin D synthase (L-PGDS) mRNA (Ptgds) expression in ECs isolated from mouse melanoma. Read More

    Treatment of Ipilimumab-Induced Vogt-Koyanagi-Harada Syndrome With Oral Dexamethasone.
    Ophthalmic Surg Lasers Imaging Retina 2017 Nov;48(11):928-931
    The author presents a retrospective case report of a 54-year-old male with ipilimumab (Yervoy; Bristol-Myers Squibb, New York City, NY)-induced Vogt-Koyanagi-Harada Disease (VKH), which consisted of uveitis, optic neuritis, and choroiditis that was successfully treated with oral dexamethasone. The patient demonstrated resolution of uveitis, optic neuritis, and choroiditis 1 month following initiation of oral dexamethasone. Ipilimumab is a recently approved therapy for malignant melanoma. Read More

    TRPM5 mediates acidic extracellular pH signaling and TRPM5 inhibition reduces spontaneous metastasis in mouse B16-BL6 melanoma cells.
    Oncotarget 2017 Oct 11;8(45):78312-78326. Epub 2017 Sep 11.
    Department of Oral Function and Molecular Biology, Ohu University School of Dentistry, Koriyama 963-8611, Japan.
    Extracellular acidity is a hallmark of solid tumors and is associated with metastasis in the tumor microenvironment. Acidic extracellular pH (pH e ) has been found to increase intracellular Ca(2+) and matrix metalloproteinase-9 (MMP-9) expression by activating NF-κB in the mouse B16 melanoma model. The present study assessed whether TRPM5, an intracellular Ca(2+)-dependent monovalent cation channel, is associated with acidic pH e signaling and induction of MMP-9 expression in this mouse melanoma model. Read More

    Dasatinib-induced Seborrheic Dermatitis-like Eruption.
    J Clin Aesthet Dermatol 2017 Jul 1;10(7):23-27. Epub 2017 Jul 1.
    Dr. Riahi is with DermSurgery Associates, Houston, Texas.
    Dasatinib is an oral tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia. It has been investigated in treating other neoplasms, including non-small-cell lung cancer and a subset of melanomas. Seborrheic dermatitis is characterized by erythematous patches or plaques with scaling typically affecting the external ear, glabella, hair-bearing areas of the face, nasolabial fold, and scalp. Read More

    Selective Killing of Melanoma Cells With Non-Thermal Atmospheric Pressure Plasma and p-FAK Antibody Conjugated Gold Nanoparticles.
    Int J Med Sci 2017 4;14(11):1101-1109. Epub 2017 Sep 4.
    Department of Oral Anatomy, School of Dentistry, Pusan National University, Yangsan 626-870, Republic of Korea.
    Melanomas are fast growing high-mortality tumors, and specific treatments for melanomas are needed. Melanoma cells overexpress focal adhesion kinase (FAK) compared to normal keratinocytes, and we sought to exploit this difference to create a selectively lethal therapy. We combined gold nanoparticles (GNP) with antibodies targeting phosphorylated FAK (p-FAK). Read More

    Long-term treatment outcomes and prognosis of mucosal melanoma of the head and neck: 161 cases from a single institution.
    Oral Oncol 2017 Nov 6;74:115-122. Epub 2017 Oct 6.
    National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China. Electronic address:
    Objectives: This study aimed to evaluate the clinical features, treatment outcomes and prognostic factors of mucosal melanoma of the head and neck (MMHN) in patients who were treated at our institution.

    Materials And Methods: Between Jan. 1981 and Oct. Read More

    Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
    Science 2017 Nov 2. Epub 2017 Nov 2.
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
    Pre-clinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti-PD-1 immunotherapy (n=112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders (R) versus non-responders (NR). Read More

    Expression of Cat Podoplanin in Feline Squamous Cell Carcinomas.
    Monoclon Antib Immunodiagn Immunother 2017 Nov 1. Epub 2017 Nov 1.
    1 Department of Antibody Drug Development, Tohoku University Graduate School of Medicine , Sendai, Miyagi, Japan .
    Oral squamous cell carcinoma is an aggressive tumor in cats; however, molecular-targeted therapies against this tumor, including antibody therapy, have not been developed. Sensitive and specific monoclonal antibodies (mAbs) against highly expressed membrane proteins are needed to develop antibody therapies. Podoplanin, a type I transmembrane glycoprotein, is expressed in many human malignant tumors, including brain tumor, esophageal cancer, lung cancer, mesothelioma, and oral cancer. Read More

    Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program.
    Ther Clin Risk Manag 2017 16;13:1423-1437. Epub 2017 Oct 16.
    Department of Neurology, Second Faculty of Medicine, Charles University, Motol University Hospital, Prague, Czech Republic.
    The introduction of high-efficacy therapies for relapsing-remitting multiple sclerosis has driven re-evaluation of treatment goals and benefit:risk considerations in treatment choice. In the alemtuzumab Phase II and III clinical trials, patients treated with alemtuzumab 12 mg versus subcutaneous interferon beta-1a demonstrated significantly reduced annualized relapse rates and improved magnetic resonance imaging outcomes, and were significantly more likely to achieve no evidence of disease activity and reduction in brain volume loss. In two of the studies, alemtuzumab-treated patients had a significantly reduced risk of 6-month confirmed disease worsening, compared with subcutaneous interferon beta-1a. Read More

    Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial.
    Eur J Cancer 2017 Nov 5;86:334-348. Epub 2017 Nov 5.
    Department of Oncology-Pathology, Karolinska University Hospital, Hospital Solma, 171 76, Stockholm, Sweden. Electronic address:
    Background: The SafeTy Events in VIsmodEgib study (STEVIE,, NCT01367665), assessed safety and efficacy of vismodegib-a first-in-class Hedgehog pathway inhibitor demonstrating clinical benefit in advanced basal cell carcinoma (BCC)-in a patient population representative of clinical practice. Primary analysis data are presented. Read More

    Case report of a KIT-mutated melanoma patient with an excellent response to apatinib and temozolomide combination therapy.
    Onco Targets Ther 2017 14;10:4553-4557. Epub 2017 Sep 14.
    Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China.
    Malignant melanoma is one kind of malignant disease which has high rates of mortality, metastasis, and poor prognosis. The therapeutic landscape is rapidly changing with the development of novel agents in recent decades, such as anti-PD-1 agents, anti-CTLA-4 agents, and BRAF inhibitors. However, since most of these novel agents are very expensive, not all patients can afford them. Read More

    Correlation of changes in HIF-1α and p53 expressions with vitamin B3 deficiency in skin cancer patients.
    G Ital Dermatol Venereol 2017 Oct 23. Epub 2017 Oct 23.
    Department of Dermatovenereology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
    Background: To investigate the correlation of changes in hypoxia-inducible factor-1α (HIF-1α) and p53 expressions with vitamin B3 deficiency in skin cancer patients.

    Methods: Twenty non-melanoma skin cancer patients with positive HIF-1α and p53 expressions were selected and randomly divided into two groups, the placebo group and the experimental group. After an appropriate number of cancer tissues were taken, the experimental group was treated with oral administration of 500 mg vitamin B3 every day, while the placebo group was treated with oral administration of the same amount of placebo; after 1 week, the skin cancer tissues in the same part were taken, and the skin tissues of healthy people were taken as the control group; the mRNA and protein expression levels of HIF-1α and p53 in tissues were detected. Read More

    World-Wide Immunoscore Task Force: meeting report from the "Melanoma Bridge", Napoli, November 30th-December 3rd, 2016.
    J Transl Med 2017 Oct 20;15(1):212. Epub 2017 Oct 20.
    Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori "Fondazione G. Pascale", Via Mariano Semmola, 80131, Naples, Italy.
    The predictive accuracy of the traditional staging system is based on disease progression as a tumour cell-autonomous process, but it fails to incorporate the effects of the host immune response. A precise analysis of the immune component of the tumour microenvironment by computer-based analysis may be essential to managing patients better, opening the road to an expertise in this new emerging field. The Immunoscore as a new possible approach in the classification of cancer, designated TNM-Immune, studied in colon cancer patients with predictive and prognostic value. Read More

    Metastatic melanoma of unknown primary in the temporalis muscle.
    BMJ Case Rep 2017 Oct 20;2017. Epub 2017 Oct 20.
    Radiology Department, Eastbourne District General Hospital, Eastbourne, UK.
    Melanomas are aggressive cancers that present as cutaneous, mucosal and ocular lesions with the ability to metastasise widely. There are, however, occasions where lesions are found in distant sites such as lymph nodes, viscera and subcutaneous tissues without clinically apparent skin involvement. This is known as metastatic melanoma of unknown primary (MUP). Read More

    Melanoma in pregnancy.
    Obstet Med 2017 Sep 20;10(3):107-112. Epub 2017 Mar 20.
    Department of Maternal-Fetal Medicine, Royal Women's Hospital, Victoria, Australia.
    Melanoma is one of the most common cancers diagnosed in pregnancy and has a high metastatic potential. As the incidence of melanoma increases, careful clinical evaluation of suspicious skin lesions remains the mainstay of early diagnosis. There is controversy in the literature as to whether pregnancy-associated melanoma has worse survival than other melanomas. Read More

    A multicenter phase I study evaluating dual PI3K and BRAF inhibition with PX-866 and vemurafenib in patients with advanced BRAF V600 mutant solid tumors.
    Clin Cancer Res 2017 Oct 19. Epub 2017 Oct 19.
    Medicine, University of Pennsylvania
    Purpose: The objectives of the study were to evaluate the safety of daily oral PX-866 in combination with twice daily vemurafenib and to identify potential predictive biomarkers for this novel combination.

    Experimental Design: We conducted a phase I, open-label, dose escalation study in patients with advanced BRAF V600 mutant solid tumors. PX-866 was administered on a continuous schedule in combination with vemurafenib. Read More

    MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.
    Clin Oral Investig 2017 Oct 15. Epub 2017 Oct 15.
    Department of Oral and Maxillofacial Plastic Surgery, University Hospital Würzburg, Pleicherwall 2, 97070, Würzburg, Germany.
    Objective: The objective of this study is to investigate the roles of melanoma-associated antigens (MAGEs) in the cisplatin treatment of head and neck cancer.

    Materials And Methods: We assessed the efficacy of cisplatin in a set of four head and neck cancer cell lines using a crystal violet assay. The MAGE-A expression in all cell lines was measured with RT-qPCR. Read More

    Rare and Extensive Malignant Melanoma of the Oral Cavity: Report of Two Cases.
    J Dent (Shiraz) 2017 Sep;18(3):227-233
    Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Islamic Azad University of Isfahan (Khorasgan), Isfahan, Iran.
    Primary oral melanomas are uncommon malignant neoplasm of melanocytes origin. The most common site of oral melanoma is maxillary gingiva and hard palate. Oral mucosal melanoma exhibit a pathobiological behavior and clinical features different from cutaneous melanomas. Read More

    Cytotoxic Effect of Thiabendazole on Hn5 Head and Neck Squamous Cell Carcinoma Cell Line.
    J Dent (Shiraz) 2017 Sep;18(3):219-226
    Craniomaxillofacial Research Center, Tehran University of Medical Sciences, Tehran, Iran.
    Statement Of The Problem: Evidence shows thiabendazole has the potential to inhibit angiogenesis in melanoma and fibrosarcoma; however, its effect on oral squamous cell carcinoma has not been previously studied.

    Purpose: This study sought to assess the cytotoxic effects of thiabendazole on HN5 head and neck squamous carcinoma cell line.

    Materials And Method: HN5 cell lines were exposed to different concentrations of thiabendazole (prepared from 99% pure powder) for 24, 48 and 72 hours. Read More

    [Potential of Using Vitamin D as an Adjuvant Treatment of Malignant Melanoma].
    Klin Onkol 2017 ;30(5):327-336
    The incidence of malignant melanoma worldwide continues to grow despite the enormous advances in topical and systemic therapy. This increase is recorded regularly even in countries where, as a result of public health campaigns, dermatological examination and subsequent treatment have become more frequent. However, there have been reports of a stable or even decreasing mortality rate that seem to contradict the objective increase in its incidence. Read More

    2-Hydroxyoleic acid-inserted liposomes as a multifunctional carrier of anticancer drugs.
    Drug Deliv 2017 Nov;24(1):1587-1597
    a Department of Bioscience and Biotechnology , Sejong University , Seoul , Republic of Korea.
    Studies have shown that insertion of oleic acid into lipid bilayers can modulate the membrane properties of liposomes so as to improve their function as drug carriers. Considering that 2-hydroxyoleic acid (2OHOA), a potential antitumor agent currently undergoing clinical trials, is a derivative of oleic acid, we explored the possibility of developing 2OHOA-inserted liposomes as a multifunctional carrier of antitumor drugs in the present study. The insertion of 2OHOA into lipid bilayers was confirmed by surface charge determination and differential scanning calorimetry. Read More

    Oral Mucosa Model for Electrochemotherapy Treatment of Dog Mouth Cancer: Ex Vivo, In Silico, and In Vivo Experiments.
    Artif Organs 2017 Oct 13. Epub 2017 Oct 13.
    Oncology Veterinary, Vet Cancer, São Paulo, Brazil.
    Electrochemotherapy (EQT) is a local cancer treatment well established to cutaneous and subcutaneous tumors. Electric fields are applied to biological tissue in order to improve membrane permeability for cytotoxic drugs. This phenomenon is called electroporation or electropermeabilization. Read More

    Natural Compound Licochalcone B Induced Extrinsic and Intrinsic Apoptosis in Human Skin Melanoma (A375) and Squamous Cell Carcinoma (A431) Cells.
    Phytother Res 2017 Oct 13. Epub 2017 Oct 13.
    Department of Pharmacy, College of Pharmacy and Natural Medicine Research Institute, Mokpo National University, Jeonnam, 534-729, Korea.
    Licochalcone B (Lico B), which is normally isolated from the roots of Glycyrrhiza inflata (Chinese Licorice), generally classified into organic compounds including retrochalcones. Potential pharmacological properties of Lico B include anti-inflammatory, anti-bacterial, anti-oxidant, and anti-cancer activities. However, its biological effects on melanoma and squamous cell carcinoma (SCC) are unknown. Read More

    Cancer incidence in urban, rural, and densely populated districts close to core cities in Bavaria, Germany.
    Int Arch Occup Environ Health 2017 Oct 12. Epub 2017 Oct 12.
    Centre for Early Cancer Detection and Cancer Registration, Bavarian Health and Food Safety Authority, Schweinauer Hauptstr. 80, 90441, Nuremberg, Germany.
    Objective: An ecologic study on the level of districts was performed to evaluate the possible association between district type and risk of cancer in Bavaria, Southern Germany.

    Methods: Cancer incidence data for the years 2003-2012 were obtained from the population-based cancer registry Bavaria according to sex and cancer site. Data on district type, socio-economic area deprivation, particulate matter exposure, tobacco consumption, and alcohol consumption were obtained from publicly available sources. Read More

    Colder environments are associated with a greater cancer incidence in the female population of the United States.
    Tumour Biol 2017 Oct;39(10):1010428317724784
    1 Department of Biochemistry, School of Life Sciences, Central University of Rajasthan, Ajmer, India.
    Cancer incidence and/or mortality among individuals varies with diet, socio-culture, ethnicity, race, gender, and age. Similarly, environmental temperature modulates many biological functions. To study the effect of environment temperature on cancer incidence, the US population was selected. Read More

    Vitamin D and the Skin: An Update for Dermatologists.
    Am J Clin Dermatol 2017 Oct 9. Epub 2017 Oct 9.
    Department of Dermatology, Hôpital Henri Mondor, 51 Avenue du Maréchal de Lattre de Tassigny, 94010, Créteil, France.
    Vitamin D plays a key role in skeletal and cardiovascular disorders, cancers, central nervous system diseases, reproductive diseases, infections, and autoimmune and dermatological disorders. The two main sources of vitamin D are sun exposure and oral intake, including vitamin D supplementation and dietary intake. Multiple factors are linked to vitamin D status, such as Fitzpatrick skin type, sex, body mass index, physical activity, alcohol intake, and vitamin D receptor polymorphisms. Read More

    Primary oral melanoma: A clinicopathologic review and case presentation.
    Quintessence Int 2017 ;48(10):815-827
    Objective: The purpose of this manuscript is to present a clinicopathologic review of the literature concerning all the detailed cases of primary oral melanoma (OM) that were confirmed by immunohistochemistry. In addition, a pertinent case presentation is addressed.

    Data Sources: An extensive electronic search of the literature was performed using PubMed/Medline from 1953 to 2017. Read More

    Melanotic Macule in Conjunction with a Giant Cell Fibroma.
    J Contemp Dent Pract 2017 Oct 1;18(10):981-985. Epub 2017 Oct 1.
    Department of Periodontology, Lake Erie College of Osteopathic Medicine, School of Dental Medicine, Bradenton, Florida, USA, Phone: +9414051506, e-mail:
    Introduction: The aim of this study is to describe a case of a melanotic macule found in conjunction with a giant cell fibroma (GCF). For oral pigmented lesions without an identifiable etiologic factor, critical factors in determining the differential diagnosis are clinical history, symmetry, and uniformity of the lesions. Potential differential diagnosis includes racial pigmentation, endocrine disturbance, Peutz-Jeghers syndrome, trauma, hemochromatosis, oral malignant melanoma, or idiopathic etiology and melanotic macules. Read More

    How many cancer cases and deaths are potentially preventable? Estimates for Australia in 2013.
    Int J Cancer 2017 Oct 6. Epub 2017 Oct 6.
    Population Health Department, QIMR Berghofer Medical Research Institute, 300 Herston Road, Herston, QLD, Australia.
    Cancer is a leading cause of disease burden in Australia, particularly fatal burden, accounting for an estimated thirty percent of deaths. Many cancers develop because of exposure to lifestyle and environmental factors that are potentially modifiable. We aimed to quantify the proportions and numbers of cancer deaths and cases in Australia in 2013 attributable to 20 modifiable factors in eight broad groupings that are established causes of cancer, namely: tobacco smoke (smoking and second-hand), dietary factors (low intake of fruit, non-starchy vegetables and dietary fibre; and high intake of red and processed meat), overweight/obesity, alcohol, physical inactivity, solar ultraviolet radiation, infections (seven agents), and reproductive factors (lack of breastfeeding, menopausal hormone therapy use, combined oral contraceptive use). Read More

    Ionic Liquid-Catalyzed Green Protocol for Multi-Component Synthesis of Dihydropyrano[2,3-c]pyrazoles as Potential Anticancer Scaffolds.
    Molecules 2017 Sep 28;22(10). Epub 2017 Sep 28.
    Y.B. Chavan College of Pharmacy, Dr. Rafiq Zakaria Campus, Rauza Baug, Aurangabad 431001, India.
    A series of 6-amino-4-substituted-3-methyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitriles 5a-j were synthesized via one-pot, four-component condensation reactions of aryl aldehydes 1a-j, propanedinitrile (2), hydrazine hydrate (3) and ethyl acetoacetate (4) under solvent-free conditions. We report herein the use of the Brønsted acid ionic liquid (BAIL) triethylammonium hydrogen sulphate [Et₃NH][HSO₄] as catalyst for this multi-component synthesis. Compared with the available reaction methodology, this new method has consistent advantages, including excellent yields, a short reaction time, mild reaction conditions and catalyst reusability. Read More

    Suppression of MAGE-A10 alters the metastatic phenotype of tongue squamous cell carcinoma cells.
    Biochem Biophys Rep 2017 Jul 19;10:267-275. Epub 2017 Apr 19.
    Instituto de Bioquímica Médica Leopoldo de Meis, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro Ilha do Fundão CEP 21941-902 Rio de Janeiro, Brazil.
    MAGE-A10 is a member of the MAGE protein family (melanoma associated antigen) which is overexpressed in cancer cells. Although MAGE-A10 has been characterized for some time and is generally associated to metastasis its function remains unknown. Here we describe experiments using as models oral squamous cell carcinoma (OSCC) cell lines displaying increasing metastatic potential (LN1 and LN2). Read More

    RIG-I-Like Receptor Signaling in Singleton-Merten Syndrome.
    Front Genet 2017 12;8:118. Epub 2017 Sep 12.
    Faculty of Dentistry, University of British Columbia, VancouverBC, Canada.
    Singleton-Merten syndrome (SMS) is an autosomal dominant, multi-system innate immune disorder characterized by early and severe aortic and valvular calcification, dental and skeletal abnormalities, psoriasis, glaucoma, and other varying clinical findings. Recently we identified a specific gain-of-function mutation in IFIH1, interferon induced with helicase C domain 1, segregated with this disease. SMS disease without hallmark dental anomalies, termed atypical SMS, has recently been reported caused by variants in DDX58, DEXD/H-box helicase 58. Read More

    Activity and safety of crizotinib in patients with advanced clear cell sarcoma with MET alterations. European Organization for Research and Treatment of Cancer phase 2 trial 90101 "CREATE".
    Ann Oncol 2017 Sep 18. Epub 2017 Sep 18.
    Department of Internal Medicine, West German Cancer Center, University Hospital, University of Duisburg-Essen, Germany.
    Background: Clear cell sarcoma (CCSA) is an orphan malignancy, characterised by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the efficacy and safety of the tyrosine kinase inhibitor (TKI) crizotinib in patients with advanced or metastatic CCSA.

    Patients And Methods: Patients with CCSA received oral crizotinib 250 mg twice daily. Read More

    Synergistic effects of interferon-beta and nivolumab in oral mucosal melanoma.
    J Dermatol 2017 Sep 25. Epub 2017 Sep 25.
    Department of Dermatology, Jichi Medical University, Shimotsuke, Japan.
    Mucosal melanoma is a rare aggressive cancer with a very poor prognosis. Clinical and pathological characteristics of mucosal melanoma differ from those of cutaneous melanoma and there are no established management guidelines for mucosal melanoma. Complete surgical excision is one of the most effective treatments for localized lesions, while targeted therapies and immunotherapies, such as monoclonal antibodies that target cytotoxic T-lymphocyte-associated molecule-4, and the programmed death (PD)-1/PD-ligand 1 pathway inhibitors, are treatment options for unresectable or metastatic lesions. Read More

    Predictors of survival in head and neck mucosal melanoma.
    Oral Oncol 2017 Oct 10;73:36-42. Epub 2017 Aug 10.
    Department of Radiation Oncology, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA; Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, 8700 Beverly Blvd., Los Angeles, CA 90048, USA. Electronic address:
    Objectives: To evaluate hospital-based data of head and neck mucosal melanoma patients in order to identify predictors of survival.

    Materials And Methods: The National Cancer Data Base was used to identify 1368 patients with head and neck mucosal melanoma diagnosed between the years of 2004 and 2012. The Kaplan-Meier method was utilized to estimate overall survival, and multivariate Cox regression analyses were performed to assess the impact of covariates on survival after adjusting for confounding variables. Read More

    Computed tomographic appearance of canine tonsillar neoplasia: 14 cases.
    Vet Radiol Ultrasound 2017 Sep 19. Epub 2017 Sep 19.
    Royal (Dick) School of Veterinary Studies, Roslin Institute, University of Edinburgh, Roslin, EH25 9RG, UK.
    The palatine tonsil is an uncommon site of oral canine neoplasia. For affected tonsils, squamous cell carcinoma is the most frequent type of neoplasia, followed by melanoma and lymphoma. Computed tomography (CT) is increasingly used for investigation of canine oropharyngeal pathology; however, limited information is available on the CT appearance of tonsillar neoplasms. Read More

    Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
    Pigment Cell Melanoma Res 2017 Sep 16. Epub 2017 Sep 16.
    UCSF Melanoma Oncology, San Francisco, CA, USA.
    Aberrant MAPK and PI3K pathway signaling may drive the malignant phenotype in NRAS-mutant and BRAF(WT) NRAS(WT) metastatic melanoma. To target these pathways, NRAS-mutant and BRAF(WT) NRAS(WT) patients received oral trametinib at 1.5 mg daily and GSK2141795 at 50 mg daily in a two-cohort Simon two-stage design. Read More

    The dosage-dependent effect exerted by the NM23-H1/H2 homolog NDK-1 on distal tip cell migration in C. elegans.
    Lab Invest 2017 Sep 18. Epub 2017 Sep 18.
    Department of Biological Anthropology, ELTE Eötvös Loránd University, Budapest, Hungary.
    Abnormal regulation of cell migration and altered rearrangement of the cytoskeleton are fundamental properties of metastatic cells. The first identified metastasis suppressor NM23-H1, which displays nucleoside-diphosphate kinase (NDPK) activity is involved in these processes. NM23-H1 inhibits the migratory and invasive potential of some cancer cells. Read More

    Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.
    Onco Targets Ther 2017 29;10:4239-4250. Epub 2017 Aug 29.
    Department of Thoracic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Magnolia Drive, Tampa, FL, USA.
    Background: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriate dose for Phase II studies, characterize pharmacokinetic and pharmacodynamic parameters, and assess antitumor activity.

    Methods: Omaveloxolone was administered orally once daily continuously in a 28-day cycle for patients with stage 4 relapsed/refractory melanoma or non-small cell lung cancer. Read More

    Gene expression profiles of cell adhesion molecules, matrix metalloproteinases and their tissue inhibitors in canine oral tumors.
    Res Vet Sci 2017 Aug 8;113:94-100. Epub 2017 Sep 8.
    Biochemistry Unit, Department of Physiology, Faculty of Veterinary Science, Chulalongkorn University, 39 Henri Dunant Rd., Pathumwan, Bangkok 10330, Thailand; Companion Animal Cancer Research Unit, Faculty of Veterinary Science, Chulalongkorn University, 39 Henri Dunant Rd., Pathumwan, Bangkok 10330, Thailand. Electronic address:
    Perturbation of cell adhesion can be essential for tumor cell invasion and metastasis, but the current knowledge on the gene expression of molecules that mediate cell adhesion in canine oral tumors is limited. The present study aimed to investigate changes in the gene expression of cell adhesion molecules (E-cadherin or CDH1, syndecan 1 or SDC1, NECTIN2 and NECTIN4), matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs), in canine oral tumors, including benign tumors, oral melanoma (OM) and non-tonsillar oral squamous cell carcinoma (OSCC), by quantitative real-time reverse transcription PCR. When compared with the normal gingival controls, decreased CDH1, SDC1 and NECTIN4 expression levels were observed in OSCC and OM, reflecting a possible role as cell adhesion molecules and tumor suppressors in canine oral cancers in contrast to the upregulation of MMP2 expression. Read More

    GUCY2C Signaling Opposes the Acute Radiation-Induced GI Syndrome.
    Cancer Res 2017 Sep;77(18):5095-5106
    Department of Pharmacology and Experimental Therapeutics, Thomas Jefferson University, Philadelphia, Pennsylvania.
    High doses of ionizing radiation induce acute damage to epithelial cells of the gastrointestinal (GI) tract, mediating toxicities restricting the therapeutic efficacy of radiation in cancer and morbidity and mortality in nuclear disasters. No approved prophylaxis or therapy exists for these toxicities, in part reflecting an incomplete understanding of mechanisms contributing to the acute radiation-induced GI syndrome (RIGS). Guanylate cyclase C (GUCY2C) and its hormones guanylin and uroguanylin have recently emerged as one paracrine axis defending intestinal mucosal integrity against mutational, chemical, and inflammatory injury. Read More

    Uncarboxylated Osteocalcin Induces Antitumor Immunity against Mouse Melanoma Cell Growth.
    J Cancer 2017 2;8(13):2478-2486. Epub 2017 Aug 2.
    Laboratory of Molecular and Cellular Biochemistry, Faculty of Dental Science, Kyushu University, Fukuoka 812-8582, Japan.
    Because of the poor response to chemotherapy and radiation therapy, new treatment approaches by immune-based therapy involving activated T cells are required for melanoma. We previously reported that the uncarboxylated form of osteocalcin (GluOC), derived from osteoblasts, potentially suppresses human prostate cancer cell proliferation by direct suppression of cell growth. However, the mechanisms in vivo have not been elucidated. Read More

    1 OF 72